Erik Hasenoehrl

Statistics

Publications

Citations

488

H-Index

Active since

2017

Affiliations

Albert Einstein College of Medicine(Current)

University of Otago

Maurice Wilkins Centre

Nanyang Technological University

Cornell University

Erik Hasenoehrl is an author at Albert Einstein College of Medicine specializing in pharmacology, mycobacterium tuberculosis infection, and enzyme inhibition.

ORCID

Publications per year

2017–2022

Publications

Exploiting the synthetic lethality between terminal respiratory oxidases to kill <i>Mycobacterium tuberculosis</i> and clear host infection

Nitin Pal Kalia, Erik Hasenoehrl, Nurlilah B. Ab Rahman et al. · Proceedings of the National Academy of Sciences · 2017 · 193 citations

Medicine, Molecular Biology, Pharmacology +14

Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis

Bei Shi Lee, Kiel Hards, Curtis A. Engelhart et al. · EMBO Molecular Medicine · 2020 · 97 citations · Full text

Life Sciences, Immunology, Microbiology +15

Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection

Erik Hasenoehrl, Dannah Rae Sajorda, Linda Berney‐Meyer et al. · Nature Communications · 2019 · 79 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria

Bei Shi Lee, Nitin Pal Kalia, Xin Jin et al. · Journal of Biological Chemistry · 2018 · 74 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis

Kiel Hards, Chen‐Yi Cheung, Natalie J.E. Waller et al. · Communications Biology · 2022 · 45 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

1–5 of 5